AUC	Area under the curve
CA-125	Cancer antigen 125
CI	Confidence interval
CGIG	Gynecologic Cancer InterGroup
CR	Complete response
CTCAE	Common Terminology Criteria for Adverse Events
eGFR	Estimated glomerular filtration rate
HIPEC	Hyperthermic intraperitoneal chemotherapy
HR	Hazard ratio
HRD	Homologous recombination deficiency
IP	Intraperitoneal
IV	Intravenous
OS	Overall survival
PARPi	Poly(ADP-ribose) polymerase inhibitor
PD	Progressive disease
PFS	Progression-free survival
PLD	Pegylated liposomal doxorubicin
PR	Partial response
RECIST	Response Evaluation Criteria in Solid Tumors
SD	Stable disease